Trial record 1 of 1 for:    NCT00128284
Previous Study | Return to List | Next Study

A Comparison of SmartPill Capsule With Scintigraphy for Determining Gastric Residence Time

This study has been completed.
Sponsor:
Information provided by:
The SmartPill Corporation
ClinicalTrials.gov Identifier:
NCT00128284
First received: August 8, 2005
Last updated: May 21, 2008
Last verified: May 2008
  Purpose

The purpose of this study is to determine the correlation between gastric residence time of the SmartPill Capsule and the time required for partial emptying of a standard radiolabeled meal as measured by gastric emptying scintigraphy.


Condition
Gastrointestinal Diseases
Stomach Diseases
Gastroparesis

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: A Comparison Trial of SmartPill Corporation GI Monitoring System With Scintigraphic Gastric Emptying Procedure for Determining Gastric Residence Time

Resource links provided by NLM:


Further study details as provided by The SmartPill Corporation:

Primary Outcome Measures:
  • To demonstrate the correlation between the gastric residence time as determined by SmartPill GI Monitoring System and the gastric emptying time of a radiolabeled meal in both healthy subjects and patients with documented gastroparesis. [ Time Frame: 30 minute intervals up to 6 hours ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To demonstrate that the gastric residence time as determined by SmartPill GI Monitoring System can discriminate between healthy human subjects and patients with gastroparesis [ Time Frame: Continuous time measure until capsule elimination ] [ Designated as safety issue: No ]
  • To characterize pressure patterns within the antrum and duodenum in healthy subjects and patients with documented gastroparesis [ Time Frame: Continuous time measure until capsule elimination ] [ Designated as safety issue: No ]
  • To characterize total GI transit time in healthy subjects [ Time Frame: Continuous tume measure until capsule elimination ] [ Designated as safety issue: No ]

Enrollment: 148
Study Start Date: February 2005
Study Completion Date: October 2005
Primary Completion Date: October 2005 (Final data collection date for primary outcome measure)
Groups/Cohorts
Normal
healthy adult subjects with no history or current gastrointestinal disorders or conditions
Gastroparesis
Subjects with documented gastroparesis

Detailed Description:

Gastric emptying scintigraphy is considered the gold standard for evaluating gastric emptying and is widely available. Accurate characterization of gastric emptying may guide medical and surgical treatment choices. In addition, these techniques may allow for monitoring of therapeutic results for follow-up patient management.

The SmartPill GI Monitoring System offers an alternative non-invasive method for characterizing disorders of the stomach. The system consists of an ingestible capsule that houses sensors for pH, temperature, and pressure, a receiver for receiving and storing signals from the capsule, and software for displaying data on a personal computer. The capsule samples at regular intervals and transmits the sensed pH, pressure, and temperature data to a portable receiver worn by the subject. After test completion, the recorded data is downloaded to a personal computer for subsequent evaluation.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

patients with gastroparesis referred to a tertiary motility center

Criteria

Inclusion Criteria:

Inclusion Criteria For Healthy Subjects:

  1. Healthy males and females between ages 18-65 years of age with no gastrointestinal disease as screened by the GI Disease Screening Questionnaire
  2. Average bowel movement frequency of at least one bowel movement within 48 hours
  3. Subjects with high probability for compliance and completion of the study

Inclusion Criteria For Subjects with Gastroparesis:

  1. Abnormal gastric emptying as defined by local standards and documented by nuclear medicine scintigraphy performed within the last two years.
  2. Males and females between ages 18-65 years of age.
  3. Average bowel movement frequency of at least one bowel movement within 72 hours
  4. Subjects with high probability for compliance and completion of the study
  5. Upper endoscopy or upper GI within last 3 years showing no evidence of gastric bezoar, stricture, or peptic ulcer.

Exclusion Criteria:

Exclusion Criteria For Healthy Subjects:

  1. Prior GI surgery
  2. Surgery within the past 3 months
  3. Diverticulitis
  4. Tobacco use within eight hours prior to capsule ingestion and during the 8 hour monitoring time.
  5. Alcohol use within 24 hours prior to capsule ingestion and throughout the entire monitoring period (up to 72 hours).
  6. Body mass index (BMI) > 35
  7. Allergies to components of the test meal including eggs, bread, and jam.
  8. Female of childbearing age who is not practicing birth control and/or is pregnant or lactating. (Confirm with urine pregnancy test)
  9. Cardiovascular, endocrine, renal, or other chronic disease likely to affect motility.

Exclusion Criteria For Subjects with Gastroparesis:

  1. History of gastric bezoar
  2. Severe dysphagia to solid food and pills
  3. Severe vomiting more than 1 time per day
  4. Diverticulitis
  5. Severe daily abdominal pain requiring medications for relief
  6. Severe weight loss, greater than 10 lbs over the preceding 2 months.
  7. Uncontrolled diabetes with a hemoglobin A1C greater than 10.
  8. Excessively delayed gastric emptying time: more than 90% of a standard egg meal retained after 2 hours.
  9. Previous gastro-esophageal surgery including vagotomy, fundoplication, gastric bypass, ulcer surgery.
  10. Prior GI surgery except for uncomplicated appendectomy and laparoscopic cholecystectomy
  11. Surgery within the past 3 months
  12. Tobacco use within eight hours prior to capsule ingestion and during the 8 hour monitoring time.
  13. Alcohol use within 24 hours prior to capsule ingestion and throughout the entire monitoring period (up to 72 hours).
  14. BMI > 35
  15. Allergies to components of the test meal including eggs, bread, and jam
  16. Female of childbearing age who is not practicing birth control and/or is pregnant or lactating. (Confirm with urine pregnancy test)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00128284

Locations
United States, Kansas
Division of Gastroenterology and Hepatology at KUMC
Kansas City, Kansas, United States, 66160
United States, Kentucky
University of Louisville Medical Center
Louisville, Kentucky, United States, 40292
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
United States, Michigan
University of Michigan Medical Center
Ann Arbor, Michigan, United States, 48109
United States, New York
VA Medical Center
Buffalo, New York, United States, 14215
United States, North Carolina
Wake Forest University Baptist Medical Center
Winston-Salem, North Carolina, United States, 27157
United States, Pennsylvania
Temple University Medical Center
Philadelphia, Pennsylvania, United States, 19140
Sponsors and Collaborators
The SmartPill Corporation
Investigators
Study Director: Jack Semler, PhD SmartPill Corporation
Principal Investigator: Braden Kuo, MD Massachusetts General Hospital
  More Information

No publications provided

Responsible Party: John R. Semler/Chief Technology Officer, The SmartPill Corporation
ClinicalTrials.gov Identifier: NCT00128284     History of Changes
Other Study ID Numbers: 102204, NYSTAR C020118, NIH DK069614
Study First Received: August 8, 2005
Last Updated: May 21, 2008
Health Authority: United States: Institutional Review Board

Keywords provided by The SmartPill Corporation:
gastroparesis
Digestive
Gastrointestinal
Stomach
Motility
Non-Invasive
Capsule
GI
Device
Digestive System Diseases

Additional relevant MeSH terms:
Gastrointestinal Diseases
Digestive System Diseases
Stomach Diseases
Gastroparesis
Paralysis
Neurologic Manifestations
Signs and Symptoms

ClinicalTrials.gov processed this record on August 20, 2014